AB-related Paper Published in the American Scientific Journal Science

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding an article published in the US scientific journal Science on July 22, 2022.


This article reported that a research paper on Aβ*56, a type of Aβ oligomer, is under investigation for its credibility, but this case has no relation to lecanemab.


Lecanemab showed a correlation between Aβ removal and a slower clinical decline in Study 201, and the Phase III study Clarity AD is currently underway.


We will continue to make every effort to deliver a new treatment as soon as possible to Alzheimer's disease patients, their families, and medical professionals.

Type Press Release

Date Released July 25, 2022

Aug 4, 2022

Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...

Aug 3, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that...

Aug 3, 2022

RAHWAY, N.J. and NUTLEY, N.J., August 3, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating...

Alerts - Release page
* Required Fields